DFV890
Near Add Your Location
Accepting patients
DFV890
A Phase 1b, Open Label, Multi-center, Dose Optimization and Dose Expansion Study to Assess the Safety and Efficacy of DFV890 in Adult Patients With Myeloid Diseases
- NLRP3 Inhibitor
- Phase 1
- Has results
Showing 1-1 of 1